Dicyanogold Effects on Lymphokine Production
Author(s) -
Katherine Tepperman,
Pamela Roy,
Brian F. Moloney,
R. C. Elder
Publication year - 1999
Publication title -
metal-based drugs
Language(s) - English
Resource type - Journals
ISSN - 0793-0291
DOI - 10.1155/mbd.1999.301
Subject(s) - lymphokine , jurkat cells , creb , transcription factor , dna synthesis , transcription (linguistics) , immune system , microbiology and biotechnology , cell culture , biology , mechanism of action , dna , chemistry , in vitro , t cell , immunology , biochemistry , gene , genetics , philosophy , linguistics
Having identified dicyanogold(I) as a common metabolite of gold-based antiarthritis drugs, we are investigating the effects of the compound on the production of lymphokines. Handel, et al. 1 suggested that the transcription factor AP-1, critical to the production of a number of cytokines, might be the target for gold compounds because of a critical cysteine within its DNA binding region. Using Jurkat cells, an established cell line as a model for CD4(+) lymphocytes, we have shown that dicyanogold inhibits the binding of AP-1 to DNA and inhibits the synthesis of IL-2 mRNA and protein. In a macrophage line, THP-1, which synthesizes IL-1beta in response to mitogen, we have shown that dicyanogold inhibits the binding of a second transcription factor, CREB to DNA. Incubation of THP-1 cells with dicyanogold inhibits the production of IL-1beta mRNA. These results suggest that the mechanism of action of gold drugs may be through their interaction with transcription factors necessary for the immune activation seen in Rheumatoid Arthritis.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom